Sera Prognostics

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Sera Prognostics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials none currently recruiting 2 completed upper quartile by trial count

Sera Prognostics: 3 sponsored US clinical trials, none currently recruiting.

Sera Prognostics sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. The most-studied condition in this pipeline is Preterm Birth, with 2 trials.

Upper-quartile sponsor footprint

Sera Prognostics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

3 total, page 1 of 1

ACTIVE NOT RECRUITING NA

Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs

NCT04301518
COMPLETED

A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor

NCT02787213
COMPLETED

Proteomic Assessment of Preterm Birth

NCT01371019

Therapeutic Areas

Preterm Birth 2
Preterm Labor 1

How the Sera Prognostics archive is shaped

3 indexed studies, none listed as recruiting (0% open); 2 completed (67%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Preterm Birth (2 trials), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Sera Prognostics: archived-pipeline peers nationwide

Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Sera Prognostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Sera Prognostics10xBio22nd Century GroupAA SecordAAADRS Clinical Research Center23andMe3-C Institute for Social Development3 Waves Wellness3EO Health
Sera Prognostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sera Prognostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sera Prognostics page

3 registered trials is a research-attention snapshot, not an endorsement of Sera Prognostics or any single study.

  • None of Sera Prognostics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Preterm Birth is the condition Sera Prognostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Preterm Birth trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sera Prognostics pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.